1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Innate Pharma
  6. News
  7. Summary
    IPH   FR0010331421

INNATE PHARMA

(IPH)
  Report
Real-time Euronext Paris  -  08:00 2022-07-04 am EDT
2.720 EUR   -0.37%
06/23INNATE PHARMA : to Participate in Upcoming Investor Conference - Form 6-K
PU
06/21Top Premarket Gainers
MT
06/03SECTOR UPDATE : Health Care Stocks Flat To Lower Premarket Friday
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about INNATE PHARMA
06/23INNATE PHARMA : to Participate in Upcoming Investor Conference - Form 6-K
PU
06/03INNATE PHARMA : Announces IPH5201 Phase 2 Study in Lung Cancer - Form 6-K
PU
06/03AstraZeneca To Pay Innate Pharma $5 Million As Lung Cancer Drug Moves To Mid-stage Deve..
MT
06/03Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer
CI
05/20INNATE PHARMA : Outcome of Innate Pharma's 2022 Annual General Meeting - Form 6-K
PU
05/20Innate Pharma S.A. Announces Supervisory Board Changes
CI
05/20INNATE PHARMA : Proxy Statments
CO
05/10TRANSCRIPT : Innate Pharma S.A., Q1 2022 Earnings Call, May 10, 2022
CI
05/10INNATE PHARMA : Press Release
CO
05/10INNATE PHARMA : 1st quarter earnings
CO
05/04France's Innate Pharma Plans $75 Million Offering of American Depositary Shares
MT
04/30INNATE PHARMA : Monthly statement on outstanding equity shares and voting rights
CO
04/29INNATE PHARMA : Information candidate Supervisory Board
PU
04/29INNATE PHARMA : First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Trig..
PU
04/29Innate Pharma To Receive $50 Million From AstraZeneca As First Patient Dosed In Late-st..
MT
More most relevant news
All news about INNATE PHARMA
06/23INNATE PHARMA : to Participate in Upcoming Investor Conference - Form 6-K
PU
06/21Top Premarket Gainers
MT
06/03SECTOR UPDATE : Health Care Stocks Flat To Lower Premarket Friday
MT
06/03INNATE PHARMA : Announces IPH5201 Phase 2 Study in Lung Cancer - Form 6-K
PU
06/03Innate Pharma, Astrazeneca to Advance Antibody IPH5201 to Phase 2 Trial in Lung Cancer
MT
06/03AstraZeneca To Pay Innate Pharma $5 Million As Lung Cancer Drug Moves To Mid-stage Deve..
MT
06/03Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer
CI
05/20INNATE PHARMA : Outcome of Innate Pharma's 2022 Annual General Meeting - Form 6-K
PU
05/20Innate Pharma S.A. Announces Supervisory Board Changes
CI
05/20INNATE PHARMA : Proxy Statments
CO
More news
News in other languages on INNATE PHARMA
06/03INNATE PHARMA : plus forte hausse du marché SRD à la clôture du vendredi 3 juin 2022 -
06/03MISE À JOUR SECTORIELLE : Les actions du secteur des soins de santé sont plates ou plus ba..
06/03INNATE PHARMA : plus forte hausse du marché SRD à la mi-séance du vendredi 3 juin 2022 -
06/03Innate Pharma en tête du SRD
06/03ASTRAZENECA : vers une nouvelle étude avec Innate
06/03Contre-intuitif
06/03Les valeurs à suivre aujourd'hui à Paris - Vendredi 3 juin 2022
06/03INNATE PHARMA : paiement d'étape de cinq millions de dollars
06/03EN DIRECT DES MARCHES : Société Générale, Aperam, Carrefour, CRH, Lululemon, Citigroup, La..
06/03INNATE PHARMA : vers une étude en cancers du poumon
More news
Analyst Recommendations on INNATE PHARMA
2021ANALYST RECOMMENDATIONS : BHP, Lear, Naked Wines, Teradata, Visteon...
2021INNATE PHARMA S A : SVB Leerink Upgrades Innate Pharma to Outperform from Market Perform
MT
2020INNATE PHARMA S A : SVB Leerink Downgrades Innate Pharma to Market Perform From Outperform..
MT
2020INNATE PHARMA S A : HC Wainwright Adjusts Innate Pharma's Price Target to $11.50 From $13,..
MT
2020INNATE PHARMA S A : Goldman Sachs Starts Innate Pharma at Neutral With $4.75 Price Target
MT
More recommendations
Press releases
06/23INNATE PHARMA : to Participate in Upcoming Investor Conference - Form 6-K
PU
06/03INNATE PHARMA : Announces IPH5201 Phase 2 Study in Lung Cancer - Form 6-K
PU
05/20INNATE PHARMA : Outcome of Innate Pharma's 2022 Annual General Meeting - Form 6-K
PU
04/29INNATE PHARMA : Information candidate Supervisory Board
PU
04/29INNATE PHARMA : First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Trig..
PU
More press releases
Upcoming event on INNATE PHARMA